HRP980197B1 - GnRH ANTAGONISTS - Google Patents

GnRH ANTAGONISTS

Info

Publication number
HRP980197B1
HRP980197B1 HR980197A HRP980197A HRP980197B1 HR P980197 B1 HRP980197 B1 HR P980197B1 HR 980197 A HR980197 A HR 980197A HR P980197 A HRP980197 A HR P980197A HR P980197 B1 HRP980197 B1 HR P980197B1
Authority
HR
Croatia
Prior art keywords
gnrh antagonists
gnrh
antagonists
Prior art date
Application number
HR980197A
Other languages
English (en)
Inventor
Graeme Semple
Guangcheng Jiang
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980197(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HRP980197A2 publication Critical patent/HRP980197A2/hr
Publication of HRP980197B1 publication Critical patent/HRP980197B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HR980197A 1997-04-11 1998-04-09 GnRH ANTAGONISTS HRP980197B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists

Publications (2)

Publication Number Publication Date
HRP980197A2 HRP980197A2 (en) 1999-02-28
HRP980197B1 true HRP980197B1 (en) 2002-08-31

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980197A HRP980197B1 (en) 1997-04-11 1998-04-09 GnRH ANTAGONISTS

Country Status (37)

Country Link
US (2) US5925730A (fr)
EP (1) EP1003774B1 (fr)
JP (2) JP4249806B2 (fr)
KR (1) KR100519421B1 (fr)
CN (1) CN1230442C (fr)
AR (1) AR011217A1 (fr)
AT (1) ATE319736T1 (fr)
AU (1) AU728642B2 (fr)
BR (1) BR9808523B1 (fr)
CA (1) CA2286190C (fr)
CY (2) CY1108063T1 (fr)
CZ (1) CZ299097B6 (fr)
DE (2) DE69833751T2 (fr)
DK (1) DK1003774T3 (fr)
EE (1) EE03974B1 (fr)
ES (1) ES2260833T3 (fr)
FR (1) FR09C0028I2 (fr)
HK (1) HK1025104A1 (fr)
HR (1) HRP980197B1 (fr)
HU (1) HU224836B1 (fr)
IL (1) IL132303A0 (fr)
LU (1) LU91585I2 (fr)
MY (1) MY114811A (fr)
NL (1) NL300395I2 (fr)
NO (2) NO324991B1 (fr)
NZ (1) NZ500142A (fr)
PL (1) PL194509B1 (fr)
PT (1) PT1003774E (fr)
RU (1) RU2199549C2 (fr)
SI (1) SI1003774T1 (fr)
SK (1) SK285381B6 (fr)
TR (1) TR199902956T2 (fr)
TW (1) TW505658B (fr)
UA (1) UA58547C2 (fr)
UY (1) UY24958A1 (fr)
WO (1) WO1998046634A1 (fr)
ZA (1) ZA983062B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (fr) * 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. PROCEDE EN PHASE LIQUIDE POUR L'ELABORATION DE PEPTIDES GnRH
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP2322197A2 (fr) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Compositions pharmaceutiques comportant de la desmopressine faiblement dosee
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
US7704977B2 (en) * 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
JP2011519928A (ja) * 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
CA2751854A1 (fr) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition contenant un bisphosphonate et administration d'un medicament a base de bisphosphonate
SG175744A1 (en) 2009-04-24 2011-12-29 Polypeptide Laboratories As Method for the manufacture of degarelix
EP2424503B1 (fr) * 2009-05-01 2017-07-05 Ferring BV Composition pour le traitement du cancer de la prostate
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (fr) 2009-11-25 2011-06-03 Novetide, Ltd. Procédé de production de degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (fr) 2010-10-27 2012-05-02 Ferring B.V. Procédé pour la fabrication du degarelix et de ses intermédiaires
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
AU2011348220B2 (en) 2010-12-22 2017-09-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (fr) 2012-01-13 2013-07-18 Ferring Bv Composition pharmaceutique
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
EP3250191B1 (fr) 2015-01-29 2024-01-17 Novo Nordisk A/S Comprimés contenant un agoniste de glp-1 et revêtement gastro-résistant
WO2017103275A1 (fr) * 2015-12-17 2017-06-22 Fresenius Kabi Anti-Infectives S.R.L Procédé de fabrication de dégarélix et de ses intermédiaires
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (fr) 2017-12-05 2019-06-13 Ferring B.V. Composition comprenant du dégarélix pour une utilisation dans le traitement du cancer du sein
CN111943960B (zh) 2019-07-29 2022-02-15 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
WO2023072284A1 (fr) 2021-11-01 2023-05-04 山东绿叶制药有限公司 Antagoniste de l'hormone de libération de la gonadotropine, son procédé de préparation et son utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE593491T1 (de) * 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
CA2136079A1 (fr) * 1992-12-18 1994-07-07 Fortuna Haviv Antagonistes de lhrh presentant des residus aminoacyle modifies en position 5 et 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
RU2199549C2 (ru) 2003-02-27
JP4249806B2 (ja) 2009-04-08
SK139699A3 (en) 2000-11-07
IL132303A0 (en) 2001-03-19
KR20010006233A (ko) 2001-01-26
CY1108063T1 (el) 2012-01-25
HK1025104A1 (en) 2000-11-03
FR09C0028I2 (fr) 2010-06-11
EE03974B1 (et) 2003-02-17
DE122009000033I1 (de) 2009-09-17
CN1230442C (zh) 2005-12-07
JP2005120101A (ja) 2005-05-12
US5925730A (en) 1999-07-20
DE122009000033I2 (de) 2011-07-21
HRP980197A2 (en) 1999-02-28
NO994906L (no) 1999-12-13
EE9900479A (et) 2000-06-15
PT1003774E (pt) 2006-05-31
LU91585I2 (fr) 2009-09-17
KR100519421B1 (ko) 2005-10-06
EP1003774B1 (fr) 2006-03-08
NO994906D0 (no) 1999-10-08
AR011217A1 (es) 2000-08-02
BR9808523B1 (pt) 2010-02-09
ZA983062B (en) 1998-10-20
HUP0002704A2 (hu) 2000-12-28
MY114811A (en) 2003-01-31
UA58547C2 (uk) 2003-08-15
NL300395I2 (nl) 2010-01-04
NO2009016I2 (no) 2014-08-25
FR09C0028I1 (fr) 2009-09-25
BR9808523A (pt) 2000-05-23
TW505658B (en) 2002-10-11
JP2001523229A (ja) 2001-11-20
CA2286190A1 (fr) 1998-10-22
CY2009008I1 (el) 2012-01-25
HU224836B1 (en) 2006-03-28
AU728642B2 (en) 2001-01-11
NL300395I1 (nl) 2009-09-01
CZ358699A3 (cs) 2000-06-14
PL194509B1 (pl) 2007-06-29
JP3645255B1 (ja) 2005-05-11
UY24958A1 (es) 2001-03-16
DE69833751D1 (de) 2006-05-04
PL336213A1 (en) 2000-06-05
SI1003774T1 (sl) 2006-08-31
EP1003774A1 (fr) 2000-05-31
CY2009008I2 (el) 2012-01-25
NO2009016I1 (no) 2009-08-10
ATE319736T1 (de) 2006-03-15
CZ299097B6 (cs) 2008-04-23
NO324991B1 (no) 2008-01-14
AU6969898A (en) 1998-11-11
HUP0002704A3 (en) 2003-08-28
WO1998046634A1 (fr) 1998-10-22
NZ500142A (en) 2001-10-26
CN1259959A (zh) 2000-07-12
TR199902956T2 (xx) 2000-08-21
CA2286190C (fr) 2007-01-09
DE69833751T2 (de) 2006-11-09
US6214798B1 (en) 2001-04-10
ES2260833T3 (es) 2006-11-01
DK1003774T3 (da) 2006-07-03
SK285381B6 (sk) 2006-12-07

Similar Documents

Publication Publication Date Title
ZA983062B (en) Gnrh antagonists
HU9602550D0 (en) Gnrh antagonists
EP1022063A4 (fr) Pulverisateur
EP1007026A4 (fr) Antagonistes d'integrine
EP1012260A4 (fr) Interleukine-20
PL335999A1 (en) Substituted 3-cyanoquinolines
AP2000001795A0 (en) Substituted 4-aminothiazol-2-yol
HUP0100754A3 (en) Spraying device
LT2000093A (en) Non-peptide gnrh agents
IL134993A0 (en) New npy antagonists
ZA982225B (en) LHRH antagonists.
IL132086A0 (en) Pharmacological agents
HK1031726A1 (en) Thrombin receptor antagonists
GB9714647D0 (en) Injector
IL134175A0 (en) Endothelin antagonists
EP0903490A4 (fr) Injecteur
ZA98256B (en) Tachykinin antagonists
GB9708481D0 (en) Terminal location
GB9700491D0 (en) Injector
ZA985209B (en) Endothelin antagonists
GB2323763B (en) Ties
IL130600A0 (en) Substituted 4-benzoyl-pyrazole
GB2328228B (en) Shale-stabilizing additives
ZA985761B (en) Substituted aryluracils
IL133261A0 (en) Substituted naphthropyrans

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20170306

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20180409